Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | STK10 | O94804 | 2/20 | 0.51 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.45 |
| ▸ | TUBB | P07437 | 2/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340102 | 1.00 | FYN (0.56) | FYNSTK10SLKAPPADRA2A | |
| SCHEMBL4446297 | 0.79 | TUBB4A (0.47) | FYNSTK10SLKCYP2A6TUBB4A | |
| SCHEMBL4946960 | 0.79 | CYP2A6 (0.64) | ADRA2AADRA2BADRA2CCYP2A6ADRA1D | |
| SCHEMBL17641740 | 0.78 | NCOA1 (0.50) | FYNADRA2AADRA2BADRA2CCYP2A6 | |
| SCHEMBL10762758 | 0.77 | SIK1 (0.60) | CYP2A6CYP2E1CYP2B6CA12CA1 | |
| SCHEMBL8503242 | 0.77 | MAOB (0.52) | CYP2A6CYP2E1CYP2B6CA12CA1 | |
| SCHEMBL5991073 | 0.77 | CYP2A6 (0.47) | FYNCYP2A6TUBB4ATUBBTUBA3C | |
| SCHEMBL2898794 | 0.76 | ADRB2 (0.49) | FYNADRA1DADRA1AADRA1BALDH1A1 | |
| SCHEMBL9210379 | 0.75 | APP (0.57) | APPADRA2BHTR7CA12CA1 | |
| SCHEMBL28906270 | 0.75 | ADRA2A (0.44) | FYNSTK10SLKADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109721615-B | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20200283454-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| EP-3686201-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| CN-109721615-A | Inhibitors of influenza viruses replication and application thereof | 广东东阳光药业有限公司 | 2019-05-07 | — | — | CN | disclosed |
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| CN-101068803-A | Biaryloxymethylarene carboxylic acid compounds | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | disclosed |
| US-7208505-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1421078-B1 | INDOLE DERIVATIVES AS BETA-3 ADRENERGIC AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | LILLY CO ELI (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
| US-20050080110-A1 | Beta 3 adrenergic agonists | SALL DANIEL JON (US) | 2005-04-14 | — | — | US | disclosed |
| EP-1421078-A1 | BETA-3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003016307-A1 | β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, GSK3A | FYN 3417/4885STK10 2153/4885SLK 4168/4885 |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | FYN 3417/4885STK10 2153/4885SLK 4168/4885 |
| US-20050080110-A1 | Beta 3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | FYN 2796/4885STK10 2689/4885SLK 2083/4885 |
| US-20200283454-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | RTF2, POLRMT, RTF1 | FYN 3313/4885STK10 4065/4885SLK 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.